A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascula ...
The holidays are a time known for feasting on delicious food, but that might not be possible for people taking weight-loss drugs.
Reports of pulmonary aspiration and difficulties in diagnosing gastrointestinal complications in the perioperative period have highlighted the need for clear clinical guidance to manage these patients ...
Some of what RFK Jr. says about obesity prevention isn't new. But after having coined the catchy MAHA acronym, it’s likely ...
The use of GLP-1s is linked to improved inflammatory bowel disease outcomes in patients with concomitant inflammatory bowel ...
A study reveals that weight loss can lead to significant healthcare savings, with 7% savings for a 5% BMI reduction and 30% ...
There’s no single GLP-1 diet plan you need to follow. If you’re taking — or thinking about taking — a GLP-1 medication like ...
Research shows an average weight loss of just 5% could save an annual $153bn in medical fees and lost productivity.
The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.
Medically reviewed by Peter Weiss, MD Ozempic is the brand name of a medication called semaglutide, a glucagon-like peptide-1 ...